InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Carroll David Francis, Chief Financial Officer. Director active across 1 company, notably IVERIC bio, Inc.. Aggregated, 15 reports have been logged. Split: 0 buy · 2 sells. Total volume traded: €829k. History available since 21 December 2021. The latest transaction was filed on 26 June 2023 (Don). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Carroll David Francis
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
44,152 sharesCommon StockSEC:0001104659-23-080691:0
24,320 shares0Common StockSEC:0001410939-23-000101:0
63,500 shares@ US$2.818.9% of flowCommon StockSEC:0001410939-23-000060:0
1,829 shares@ US$1.450.1% of flowCommon StockSEC:0001410939-23-000057:0
8,750 shares0Common StockSEC:0001410939-23-000007:0
14,375 shares0Common StockSEC:0001410939-22-000136:0
10,000 shares0Common StockSEC:0001410939-22-000127:0
2,144 shares@ US$17.002.0% of flowCommon StockSEC:0001410939-22-000046:0
16,763 shares@ US$1.451.3% of flowCommon StockSEC:0001410939-22-000033:0
8,237 shares@ US$1.450.6% of flowCommon StockSEC:0001410939-22-000024:0
32,500 sharesCommon StockSEC:0001104659-22-000976:0
56,207 shares@ US$15.982648.0% of flowCommon StockSEC:0001104659-21-153088:0
14,375 sharesCommon StockSEC:0001104659-21-152294:0
12,500 sharesCommon StockSEC:0001104659-21-149632:0
10,000 sharesCommon StockSEC:0001104659-21-149245:0
15 of 15 declarations
About Carroll David Francis
Carroll David Francis serves as Senior Vice President, Chief Financial Officer, and Treasurer at IVERIC bio, Inc. He is responsible for the company's financial management, including financial planning, treasury, and financial reporting. With extensive experience in the biopharmaceutical sector, he plays a key role in optimizing financial performance and the company's investment strategy.
